TRANSMEDICS GROUP INC (TMDX) Stock Price, Quote, News and Overview
NASDAQ:TMDX - Nasdaq - US89377M1099 - Common Stock - Currency: USD
TMDX Quote, Performance and Key Statistics
118.73
+7.23 (+6.48%)
The current stock price of TMDX is 118.73 USD. In the past month the price increased by 47.34%. In the past year, price decreased by -13.95%.
TMDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.61 | 228.91B | ||
| ISRG | INTUITIVE SURGICAL INC | 73.49 | 201.23B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.1 | 152.15B | ||
| SYK | STRYKER CORP | 30.97 | 148.13B | ||
| MDT | MEDTRONIC PLC | 16.07 | 110.05B | ||
| BDX | BECTON DICKINSON AND CO | 12.44 | 50.35B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.77 | 43.97B | ||
| IDXX | IDEXX LABORATORIES INC | 44.7 | 41.29B | ||
| RMD | RESMED INC | 27.28 | 36.31B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.11 | 33.93B | ||
| DXCM | DEXCOM INC | 51.55 | 33.35B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.37 | 23.54B |
Related stock screener links
About TMDX
Company Profile
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Company Info
TRANSMEDICS GROUP INC
200 Minuteman Road
Andover MASSACHUSETTS 01810 US
CEO: Waleed H. Hassanein
Employees: 728
Phone: 19785520900
TRANSMEDICS GROUP INC / TMDX FAQ
What is the stock price of TRANSMEDICS GROUP INC today?
The current stock price of TMDX is 118.73 USD. The price increased by 6.48% in the last trading session.
What is the ticker symbol for TRANSMEDICS GROUP INC stock?
The exchange symbol of TRANSMEDICS GROUP INC is TMDX and it is listed on the Nasdaq exchange.
On which exchange is TMDX stock listed?
TMDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TRANSMEDICS GROUP INC stock?
17 analysts have analysed TMDX and the average price target is 119.85 USD. This implies a price increase of 0.94% is expected in the next year compared to the current price of 118.73. Check the TRANSMEDICS GROUP INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TRANSMEDICS GROUP INC worth?
TRANSMEDICS GROUP INC (TMDX) has a market capitalization of 4.02B USD. This makes TMDX a Mid Cap stock.
How many employees does TRANSMEDICS GROUP INC have?
TRANSMEDICS GROUP INC (TMDX) currently has 728 employees.
What are the support and resistance levels for TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a support level at 96.97. Check the full technical report for a detailed analysis of TMDX support and resistance levels.
Is TRANSMEDICS GROUP INC (TMDX) expected to grow?
The Revenue of TRANSMEDICS GROUP INC (TMDX) is expected to grow by 26.11% in the next year. Check the estimates tab for more information on the TMDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TRANSMEDICS GROUP INC (TMDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TMDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TMDX, evaluating the profitability, health, valuation and growth aspects
- TRANSMEDICS GROUP INC (TMDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TRANSMEDICS GROUP INC (TMDX) Sales and EPS estimates to see what analysts future expectations are.
- TRANSMEDICS GROUP INC (TMDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TRANSMEDICS GROUP INC (TMDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TRANSMEDICS GROUP INC (TMDX) Stock Chart to make your own analysis
- TRANSMEDICS GROUP INC (TMDX) Latest news and press-releases to stay up to date.
Does TRANSMEDICS GROUP INC (TMDX) stock pay dividends?
TMDX does not pay a dividend.
When does TRANSMEDICS GROUP INC (TMDX) report earnings?
TRANSMEDICS GROUP INC (TMDX) will report earnings on 2025-07-29, after the market close.
What is the Price/Earnings (PE) ratio of TRANSMEDICS GROUP INC (TMDX)?
The PE ratio for TRANSMEDICS GROUP INC (TMDX) is 87.3. This is based on the reported non-GAAP earnings per share of 1.36 and the current share price of 118.73 USD. Check the full fundamental report for a full analysis of the valuation metrics for TMDX.
What is the Short Interest ratio of TRANSMEDICS GROUP INC (TMDX) stock?
The outstanding short interest for TRANSMEDICS GROUP INC (TMDX) is 26.9% of its float. Check the ownership tab for more information on the TMDX short interest.
TMDX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TMDX. When comparing the yearly performance of all stocks, TMDX is one of the better performing stocks in the market, outperforming 93.03% of all stocks.
TMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TMDX. Both the profitability and the financial health of TMDX get a neutral evaluation. Nothing too spectacular is happening here.
TMDX Financial Highlights
Over the last trailing twelve months TMDX reported a non-GAAP Earnings per Share(EPS) of 1.36. The EPS increased by 500% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.03% | ||
| ROA | 4.41% | ||
| ROE | 15.51% | ||
| Debt/Equity | 2.23 |
TMDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to TMDX. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 47.95% and a revenue growth 26.11% for TMDX